Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $14.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 389.51% from the company’s current price.
Evaxion Biotech A/S Price Performance
EVAX stock opened at $2.86 on Thursday. Evaxion Biotech A/S has a fifty-two week low of $2.26 and a fifty-two week high of $13.82. The business has a 50-day moving average of $3.15 and a 200-day moving average of $3.82. The stock has a market capitalization of $15.47 million, a P/E ratio of -0.66 and a beta of -0.28.
Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report) last posted its quarterly earnings results on Tuesday, May 28th. The company reported $0.03 earnings per share (EPS) for the quarter. The firm had revenue of $0.05 million for the quarter. Equities analysts expect that Evaxion Biotech A/S will post -0.1 EPS for the current year.
Hedge Funds Weigh In On Evaxion Biotech A/S
About Evaxion Biotech A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers.
Further Reading
- Five stocks we like better than Evaxion Biotech A/S
- How to Calculate Stock Profit
- Humana Slides on Profitability Concerns Despite Q2 Earnings Beat
- How to Calculate Options Profits
- Procter & Gamble Stock Drops Despite Earnings Beat – What to Know
- Investing In Preferred Stock vs. Common Stock
- Financial Sector Shines as Key Players Continue to Beat Earnings
Receive News & Ratings for Evaxion Biotech A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion Biotech A/S and related companies with MarketBeat.com's FREE daily email newsletter.